Goldman Sachs Group Inc Rapt Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 397,753 shares of RAPT stock, worth $469,348. This represents 0.0% of its overall portfolio holdings.
Number of Shares
397,753
Previous 373,788
6.41%
Holding current value
$469,348
Previous $1.14 Million
29.91%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding RAPT
# of Institutions
104Shares Held
49.4MCall Options Held
26.7KPut Options Held
2.4K-
Medicxi Ventures Management (Jersey) LTD22.4MShares$26.4 Million7.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.16MShares$3.72 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$3.16 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$2.88 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2.04 Million0.42% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $35M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...